BRPI0921249A2 - uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer. - Google Patents

uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.

Info

Publication number
BRPI0921249A2
BRPI0921249A2 BRPI0921249-3A BRPI0921249A BRPI0921249A2 BR PI0921249 A2 BRPI0921249 A2 BR PI0921249A2 BR PI0921249 A BRPI0921249 A BR PI0921249A BR PI0921249 A2 BRPI0921249 A2 BR PI0921249A2
Authority
BR
Brazil
Prior art keywords
preparation
composition
extracellular matrix
compositions
chemotherapeutic agent
Prior art date
Application number
BRPI0921249-3A
Other languages
English (en)
Inventor
K. Naughton Gail
Pinney Emmett
Original Assignee
Histogen,Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histogen,Inc filed Critical Histogen,Inc
Publication of BRPI0921249A2 publication Critical patent/BRPI0921249A2/pt
Publication of BRPI0921249A8 publication Critical patent/BRPI0921249A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0921249A 2008-11-14 2009-01-30 uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer BRPI0921249A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11496608P 2008-11-14 2008-11-14
US61/114.966 2008-11-14
PCT/US2009/032677 WO2010056378A2 (en) 2008-11-14 2009-01-30 Extracellular matrix compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
BRPI0921249A2 true BRPI0921249A2 (pt) 2018-10-23
BRPI0921249A8 BRPI0921249A8 (pt) 2018-12-04

Family

ID=42170608

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921249A BRPI0921249A8 (pt) 2008-11-14 2009-01-30 uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer

Country Status (10)

Country Link
US (6) US8852637B2 (pt)
EP (1) EP2365815B1 (pt)
JP (1) JP5916388B2 (pt)
KR (1) KR101610985B1 (pt)
CN (1) CN102497871B (pt)
AU (1) AU2009314506B2 (pt)
BR (1) BRPI0921249A8 (pt)
CA (1) CA2743871C (pt)
RU (1) RU2523339C2 (pt)
WO (1) WO2010056378A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
WO2010056378A2 (en) 2008-11-14 2010-05-20 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
WO2013003234A1 (en) * 2011-06-28 2013-01-03 Trevigen, Inc. Tumor extract
EP2816964B1 (en) 2012-02-21 2023-12-27 Ben-Gurion University of The Negev Research and Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
US20140248371A1 (en) * 2013-01-10 2014-09-04 Carmel-Haifa University Economic Corp. Ltd. Spalax fibroblast-derived anti-cancer agents
SG11201506312TA (en) 2013-02-12 2015-09-29 Replicel Life Sciences Inc Compositions and methods for treating and repairing tendons
US10533191B2 (en) 2014-01-15 2020-01-14 Serucell Corporation Therapeutic serum obtained from co-cultured cells
WO2015123477A1 (en) 2014-02-12 2015-08-20 Replicel Life Sciences Inc. Compositions and methods for treating bone, joints and cartilage
AU2015231110B2 (en) 2014-03-21 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
EP3288565A4 (en) * 2015-04-30 2019-02-13 Histogen, Inc. EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER OR IMMUNE DISEASES
WO2017118979A1 (en) 2016-01-07 2017-07-13 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions and methods for generating immunotolerant responses
JP6757578B2 (ja) * 2016-03-15 2020-09-23 メビオール株式会社 Ｔｇｐ含有保存液と微小重力負荷による免疫細胞及び血液細胞の機能増強方法
IL262180B2 (en) * 2016-04-12 2025-12-01 Illustris Pharmaceuticals Inc Compositions for topical application of compounds
CA3049990A1 (en) 2017-03-02 2018-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer
CN107349417A (zh) * 2017-04-01 2017-11-17 南阳市中心医院 一种治疗食管鳞癌的ecm复合物以及其在制备治疗食管鳞癌的药物中的用途
US11718829B2 (en) 2017-07-28 2023-08-08 Breakthrough Tech Llc Methods and compositions for manufacturing extracellular matrix
MY210233A (en) * 2017-10-11 2025-09-04 Illustris Pharmaceuticals Inc Methods and compositions for topical delivery
CN108424878A (zh) * 2018-03-26 2018-08-21 南通大学附属医院 乳腺癌及乳腺组织ecm及其制备方法和乳腺癌3d体外培养模型的构建方法
CA3107592A1 (en) * 2018-08-02 2020-02-06 Histogen, Inc. Conditioned medium and extracellular matrix compositions and uses thereof
KR20200040536A (ko) * 2018-10-10 2020-04-20 사회복지법인 삼성생명공익재단 저산소 조건에서 섬유아세포를 배양하여 제조한 조정배지를 포함하는 암세포 사멸 유도용 조성물 및 이의 제조 방법
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof
TWI888659B (zh) * 2021-10-13 2025-07-01 芯芮生技開發股份有限公司 幹細胞條件培養基於製備抑制癌症組成物的用途
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
BE1031361B1 (fr) * 2023-02-20 2024-09-23 Novadip Biosciences Utilisation d'une composition comprenant une matrice extracellulaire neo-synthetisee pour le traitement du cancer, en particulier pour l'inhibition de la viabilite, de la migration et de la proliferation du cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5750146A (en) 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug
US5830708A (en) * 1995-06-06 1998-11-03 Advanced Tissue Sciences, Inc. Methods for production of a naturally secreted extracellular matrix
KR19980068378A (ko) 1997-02-19 1998-10-15 김광호 액정 프로젝터의 광학장치
US6197586B1 (en) * 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
WO1999051246A1 (en) 1998-04-03 1999-10-14 Ajinomoto Co., Inc. Antitumor agents
EP2295540A1 (en) * 1998-11-19 2011-03-16 Organogenesis, Inc. Bioengineered tissue constructs and methods for producing and using them
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
WO2003020172A1 (en) * 2001-08-29 2003-03-13 De Carvalho Ricardo A P An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
AU2005300263A1 (en) * 2004-03-09 2006-05-11 Jan-Eric W. Ahlfors Autogenic living scaffolds and living tissue matrices: methods and uses thereof
WO2005104766A2 (en) * 2004-04-28 2005-11-10 Myocardial Therapeutics, Inc. Injection of bone marrow-derived conditioned medium for angiogenesis
PL1759536T3 (pl) * 2004-06-01 2011-10-31 Kwalata Trading Ltd Techniki in vitro z użyciem komórek macierzystych
AU2005279934A1 (en) 2004-08-30 2006-03-09 Theregen, Inc. Compositions and methods of promoting hair growth
WO2006052852A2 (en) 2004-11-04 2006-05-18 Hemogenix, Inc. Kit for in process quality control to predict and determine engraftment and multilineage reconstitution potential of hematopoietic cells and cord blood storage
DE602005026866D1 (de) 2004-11-22 2011-04-21 Theregen Inc Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ES2388068T3 (es) 2004-12-23 2012-10-08 Molmed Spa Producto de conjugación
JP2006249031A (ja) * 2005-03-11 2006-09-21 Tokyo Univ Of Science 抗癌剤
CA2663749A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7674770B2 (en) 2007-04-11 2010-03-09 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
WO2010056378A2 (en) 2008-11-14 2010-05-20 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA2743871C (en) 2016-10-11
US9034312B2 (en) 2015-05-19
AU2009314506A1 (en) 2010-05-20
RU2011123788A (ru) 2012-12-20
US20100124573A1 (en) 2010-05-20
US9506038B2 (en) 2016-11-29
WO2010056378A2 (en) 2010-05-20
CN102497871A (zh) 2012-06-13
BRPI0921249A8 (pt) 2018-12-04
US20110097403A1 (en) 2011-04-28
KR20110106302A (ko) 2011-09-28
US8852637B2 (en) 2014-10-07
RU2523339C2 (ru) 2014-07-20
WO2010056378A3 (en) 2015-10-08
US20170071985A1 (en) 2017-03-16
US20190201439A1 (en) 2019-07-04
CA2743871A1 (en) 2010-05-20
EP2365815B1 (en) 2019-09-18
EP2365815A2 (en) 2011-09-21
CN102497871B (zh) 2014-10-15
US20200360430A1 (en) 2020-11-19
US20150246076A1 (en) 2015-09-03
US10143708B2 (en) 2018-12-04
KR101610985B1 (ko) 2016-04-08
JP2012508739A (ja) 2012-04-12
AU2009314506B2 (en) 2015-07-23
JP5916388B2 (ja) 2016-05-11
EP2365815A4 (en) 2016-11-30
US10675303B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
IL205880A0 (en) Aminoglycoside analogs, compositions comprising the same and uses thereof
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BRPI0920955A2 (pt) processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0907663A2 (pt) ''composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições.
BR112014019011A8 (pt) Composição, método para controlar a umectabilidade das superfícies do substrato, uso de uma composição, e, material
BRPI0922587A2 (pt) composição detergente para lavagem, e, uso da composição citada
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
BRPI0822220A2 (pt) Composições contendo enzima e agente de matiz para tecidos
BRPI1010903A2 (pt) partícula modificada na superfície, composição farmacêutica, método para intensificar a absorção celular de um agente ativo, uso de uma pluralidade de partículas modificadas na superfície, e, pluralidade de partículas modificadas na superfície
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
CL2013000396A1 (es) Composicion que comprende bacillus subtilis y bacillus licheniformis; proceso para elaborar dicha composicion; uso de dicha composición para el control de los fitonematodos y/o en la introduccion de una resistencia especifica a ellos.
EP2166058A4 (en) FRUIT COMPOSITION AND FRUIT THEREOF
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI0813680A8 (pt) composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0821636A2 (pt) Uso de um agente de mascaramento de sabor, composição líquida, e, uso da composição líquida
BRPI0814420A2 (pt) composição, e, uso de álcool alcoxilado.
UY32659A (es) Pirazinilpirazoles

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA 6A, 7A 8A E 9A ANUIDADES, DE ACORDO COM TABELA VIGENTE, REFERENTE AS GUIAS DE RECOLHIMENTO 0000921500701490, 0000921600783790, 0000921700864377 E 29409161801083524, RESPECTIVAMENTE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.5 NA RPI NO 2498 DE 21/11/2018.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL